Emerging frontiers in androgen receptor research for prostate Cancer: insights from the 2nd international androgen receptor Symposium.
AR
Androgen deprivation therapy
NR3C4
PCa
PSMA
Journal
Journal of experimental & clinical cancer research : CR
ISSN: 1756-9966
Titre abrégé: J Exp Clin Cancer Res
Pays: England
ID NLM: 8308647
Informations de publication
Date de publication:
17 Jul 2024
17 Jul 2024
Historique:
received:
15
06
2024
accepted:
11
07
2024
medline:
17
7
2024
pubmed:
17
7
2024
entrez:
16
7
2024
Statut:
epublish
Résumé
Continued exploration of the androgen receptor (AR) is crucial, as it plays pivotal roles in diverse diseases such as prostate cancer (PCa), serving as a significant therapeutic focus. Therefore, the Department of Urology Dresden hosted an international meeting for scientists and clinical oncologists to discuss the newest advances in AR research. The 2nd International Androgen Receptor Symposium was held in Dresden, Saxony, Germany, from 26-27.04.2024, organised by Dr. Holger H.H. Erb. Following the format of the first meeting, more than 35 scientists from 8 countries attended the event to discuss recent developments, research challenges, and identification of venues in AR research. An important new feature was the involvement of PhD students and young investigators, acknowledging the high scientific quality of their work. The symposium included three covers: new advances from clinical research, basic and translational research, and novel strategies to target AR. Moreover, based on its increasing clinical relevance, a PSMA theranostic mini-symposium was added at the end of the AR symposium to allow the audience to discuss the newest advances in PSMA theranostic. This report focuses on the highlights and discussions of the meeting.
Identifiants
pubmed: 39014480
doi: 10.1186/s13046-024-03125-5
pii: 10.1186/s13046-024-03125-5
doi:
Substances chimiques
AR protein, human
0
Receptors, Androgen
0
Types de publication
Congress
Langues
eng
Sous-ensembles de citation
IM
Pagination
194Informations de copyright
© 2024. The Author(s).
Références
Mehralivand S, Thomas C, Puhr M, Claessens F, van de Merbel AF, Dubrovska A et al. New advances of the androgen receptor in prostate cancer: report from the 1st International Androgen Receptor Symposium. J Transl Med. 2024;22(1):71.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021.
Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Pineros M, Znaor A et al. Cancer statistics for the year 2020: an overview. Int J Cancer. 2021.
Isaacs JT. Resolving the Coffey Paradox: what does the androgen receptor do in normal vs. malignant prostate epithelial cells? Am J Clin Experimental Urol. 2018;6(2):55–61.
Pisano C, Tucci M, Di Stefano RF, Turco F, Scagliotti GV, Di Maio M, et al. Interactions between androgen receptor signaling and other molecular pathways in prostate cancer progression: current and future clinical implications. Crit Rev Oncol Hematol. 2021;157:103185.
pubmed: 33341506
doi: 10.1016/j.critrevonc.2020.103185
Beier AK, Puhr M, Stope MB, Thomas C, Erb HHH. Metabolic changes during prostate cancer development and progression. J Cancer Res Clin Oncol. 2023;149(5):2259–70.
pubmed: 36151426
doi: 10.1007/s00432-022-04371-w
Uo T, Sprenger CC, Plymate SR. Androgen receptor signaling and metabolic and Cellular Plasticity during Progression to Castration resistant prostate Cancer. Front Oncol. 2020;10:580617.
pubmed: 33163409
pmcid: 7581990
doi: 10.3389/fonc.2020.580617
Polkinghorn WR, Parker JS, Lee MX, Kass EM, Spratt DE, Iaquinta PJ, et al. Androgen receptor signaling regulates DNA repair in prostate cancers. Cancer Discov. 2013;3(11):1245–53.
pubmed: 24027196
pmcid: 3888815
doi: 10.1158/2159-8290.CD-13-0172
Shiota M, Yokomizo A, Naito S. Pro-survival and anti-apoptotic properties of androgen receptor signaling by oxidative stress promote treatment resistance in prostate cancer. Endocrine-related Cancer. 2012;19.
Schiewer MJ, Augello MA, Knudsen KE. The AR dependent cell cycle: mechanisms and cancer relevance. Mol Cell Endocrinol. 2012;352(1–2):34–45.
pubmed: 21782001
doi: 10.1016/j.mce.2011.06.033
Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate Cancer-2024 update. Part I: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2024.
Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate Cancer. Part II-2020 update: treatment of relapsing and metastatic prostate Cancer. Eur Urol. 2021;79(2):263–82.
pubmed: 33039206
doi: 10.1016/j.eururo.2020.09.046
Hodges C. Studies on prostatic cancer I. the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1(4):293–7.
Santer FR, Erb HH, McNeill RV. Therapy escape mechanisms in the malignant prostate. Sem Cancer Biol. 2015;35:133–44.
doi: 10.1016/j.semcancer.2015.08.005
Claessens F, Helsen C, Prekovic S, Van den Broeck T, Spans L, Van Poppel H, et al. Emerging mechanisms of enzalutamide resistance in prostate cancer. Nat Rev Urol. 2014;11(12):712–6.
pubmed: 25224448
doi: 10.1038/nrurol.2014.243
Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14(2):149–58.
pubmed: 23306100
doi: 10.1016/S1470-2045(12)70560-0
Thomas C, Baunacke M, Erb HHH, Füssel S, Erdmann K, Putz J et al. Systemic triple therapy in metastatic hormone-sensitive prostate Cancer (mHSPC): ready for Prime Time or still to be. Explored? Cancers. 2021;14(1).
Wang L, Paller CJ, Hong H, De Felice A, Alexander GC, Brawley O. Comparison of systemic treatments for metastatic castration-sensitive prostate Cancer: a systematic review and network Meta-analysis. JAMA Oncol. 2021;7(3):412–20.
pubmed: 33443584
pmcid: 7809610
doi: 10.1001/jamaoncol.2020.6973
Mandel P, Hoeh B, Wenzel M, Preisser F, Tian Z, Tilki D, et al. Triplet or Doublet Therapy in metastatic hormone-sensitive prostate Cancer patients: a systematic review and network Meta-analysis. Eur Urol Focus. 2023;9(1):96–105.
pubmed: 36058809
doi: 10.1016/j.euf.2022.08.007
Hussain M, Kocherginsky M, Agarwal N, Adra N, Zhang J, Paller C, et al. BRCAAway: a randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) bearing homologous recombination-repair mutations (HRRm). J Clin Oncol. 2024;42:19.
doi: 10.1200/JCO.2024.42.4_suppl.19
Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, et al. [< sup > 177 Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397(10276):797–804.
pubmed: 33581798
doi: 10.1016/S0140-6736(21)00237-3
Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177–PSMA-617 for metastatic castration-resistant prostate Cancer. N Engl J Med. 2021;385(12):1091–103.
pubmed: 34161051
pmcid: 8446332
doi: 10.1056/NEJMoa2107322
Hofman MS, Emmett L, Sandhu S, Iravani A, Buteau JP, Joshua AM, et al. Overall survival with [(177)Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial. Lancet Oncol. 2024;25(1):99–107.
pubmed: 38043558
doi: 10.1016/S1470-2045(23)00529-6
Buteau J, Martin A, Emmett L, Iravani A, Sandhu S, Joshua A, et al. PSMA PET and FDG PET as predictors of response and prognosis in a randomized phase 2 trial of 177 Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic, castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603). J Clin Oncol. 2022;40:10.
doi: 10.1200/JCO.2022.40.6_suppl.010
Chen Q-H, Munoz E, Ashong D. Insight into recent advances in degrading androgen receptor for castration-resistant prostate Cancer. Cancers [Internet]. 2024; 16(3).
Gao X, Iii H, Vuky J, Dreicer R, Sartor A, Sternberg C, et al. Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2022;40:17.
doi: 10.1200/JCO.2022.40.6_suppl.017
Petrylak D, Garmezy B, Shen J, Kalebasty A, Sartor O, Dreicer R, et al. 1803P phase I/II study of bavdegalutamide, a PROTAC androgen receptor (AR) degrader in metastatic castration-resistant prostate cancer (mCRPC): Radiographic progression-free survival (rPFS) in patients (pts) with AR ligand-binding domain (LBD) mutations. Ann Oncol. 2023;34:S973–4.
doi: 10.1016/j.annonc.2023.09.2751
Petrylak D, Stewart T, Gao X, Berghorn E, Lu H, Chan E, et al. A phase 2 expansion study of ARV-766, a PROTACandrogen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2023;41:TPS290–TPS.
doi: 10.1200/JCO.2023.41.6_suppl.TPS290
Bernard-Tessier A, Mulier G, Nay P, Baldini C, Albiges L, Colomba E, et al. Androgen receptor (AR) mutations in men with metastatic castration-resistant prostate cancer (mCRPC): incidence and natural history. J Clin Oncol. 2023;41:221.
doi: 10.1200/JCO.2023.41.6_suppl.221
Antonarakis E, Zhang N, Saha J, Nevalaita L, Shell S, Garratt C et al. REAL-WORLD ASSESSMENT OF AR-LBD MUTATIONS IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER2023.
Crippa A, De Laere B, Discacciati A, Larsson B, Connor JT, Gabriel EE, et al. The ProBio trial: molecular biomarkers for advancing personalized treatment decision in patients with metastatic castration-resistant prostate cancer. Trials. 2020;21(1):579.
pubmed: 32586393
pmcid: 7318749
doi: 10.1186/s13063-020-04515-8
Kreuz M, Otto DJ, Fuessel S, Blumert C, Bertram C, Bartsch S, et al. ProstaTrend-A Multivariable Prognostic RNA expression score for aggressive prostate Cancer. Eur Urol. 2020;78(3):452–9.
pubmed: 32631745
doi: 10.1016/j.eururo.2020.06.001
Ebersbach C, Beier A-MK, Hönscheid P, Sperling C, Jöhrens K, Baretton GB et al. Influence of systemic therapy on the expression and activity of selected STAT proteins in prostate Cancer tissue. Life. 2022;12(2).
Ebersbach C, Beier A-MK, Thomas C, Erb HHH. Impact of STAT proteins in Tumor Progress and Therapy Resistance in Advanced and metastasized prostate Cancer. Cancers. 2021;13(19):4854.
pubmed: 34638338
pmcid: 8508518
doi: 10.3390/cancers13194854
Puhr M, Hoefer J, Eigentler A, Ploner C, Handle F, Schaefer G, et al. The glucocorticoid receptor is a key player for prostate Cancer cell survival and a target for Improved Antiandrogen Therapy. Clin cancer Research: Official J Am Association Cancer Res. 2018;24(4):927–38.
doi: 10.1158/1078-0432.CCR-17-0989
Erb HH, Bodenbender J, Handle F, Diehl T, Donix L, Tsaur I, et al. Assessment of STAT5 as a potential therapy target in enzalutamide-resistant prostate cancer. PLoS ONE. 2020;15(8):e0237248.
pubmed: 32790723
pmcid: 7425943
doi: 10.1371/journal.pone.0237248
Arora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, Balbas MD, et al. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell. 2013;155(6):1309–22.
pubmed: 24315100
pmcid: 3932525
doi: 10.1016/j.cell.2013.11.012
Desai K, Serritella AV, Stadler WM, O’Donnell PH, Sweis RF, Szmulewitz RZ. Phase I trial of enzalutamide (Enz) plus the glucocorticoid receptor antagonist relacorilant (rela) for patients with metastatic castration resistant prostate cancer. J Clin Oncol. 2023;41(16suppl):5062.
doi: 10.1200/JCO.2023.41.16_suppl.5062
Serritella AV, Shevrin D, Heath EI, Wade JL, Martinez E, Anderson A, et al. Phase I/II trial of Enzalutamide and Mifepristone, a glucocorticoid receptor antagonist, for metastatic castration-resistant prostate Cancer. Clin cancer Research: Official J Am Association Cancer Res. 2022;28(8):1549–59.
doi: 10.1158/1078-0432.CCR-21-4049
Abida W, Hahn AW, Shore N, Agarwal N, Sieber P, Smith MR, et al. Phase I study of ORIC-101, a glucocorticoid receptor antagonist, in combination with Enzalutamide in patients with metastatic castration-resistant prostate Cancer progressing on Enzalutamide. Clin cancer Research: Official J Am Association Cancer Res. 2024;30(6):1111–20.
doi: 10.1158/1078-0432.CCR-23-3508
Morris MJ, Linch MD, Crabb SJ, Beer TM, Heath EI, Gordon MS, et al. Phase 1 efficacy and pharmacodynamic results of exicorilant + enzalutamide in patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2023;41(6suppl):145.
doi: 10.1200/JCO.2023.41.6_suppl.145
Eigentler A, Handle F, Schanung S, Degen A, Hackl H, Erb HHH, et al. Glucocorticoid treatment influences prostate cancer cell growth and the tumor microenvironment via altered glucocorticoid receptor signaling in prostate fibroblasts. Oncogene. 2024;43(4):235–47.
pubmed: 38017134
doi: 10.1038/s41388-023-02901-5
Linxweiler J, Hajili T, Körbel C, Berchem C, Zeuschner P, Müller A, et al. Cancer-associated fibroblasts stimulate primary tumor growth and metastatic spread in an orthotopic prostate cancer xenograft model. Sci Rep. 2020;10(1):12575.
pubmed: 32724081
pmcid: 7387494
doi: 10.1038/s41598-020-69424-x
Taurozzi AJ, Beekharry R, Wantoch M, Labarthe M-C, Walker HF, Seed RI, et al. Spontaneous development of Epstein-Barr virus associated human lymphomas in a prostate cancer xenograft program. PLoS ONE. 2017;12(11):e0188228.
pubmed: 29145505
pmcid: 5690647
doi: 10.1371/journal.pone.0188228
Saar M, Körbel C, Linxweiler J, Jung V, Hasenfus A, Stöckle M et al. Orthotopic tumorgrafts in nude mice: a new method to study human prostate cancer. Prostate. 2015;13.
Sailer V, von Amsberg G, Duensing S, Kirfel J, Lieb V, Metzger E, et al. Experimental in vitro, ex vivo and in vivo models in prostate cancer research. Nat Rev Urol. 2023;20(3):158–78.
pubmed: 36451039
doi: 10.1038/s41585-022-00677-z
ERB HHH, OSTER MA, GELBRICH N, CAMMANN C, THOMAS C, MUSTEA A, et al. Enzalutamide-induced proteolytic degradation of the androgen receptor in prostate Cancer cells is mediated only to a limited extent by the Proteasome System. Anticancer Res. 2021;41(7):3271–9.
pubmed: 34230121
doi: 10.21873/anticanres.15113
Siciliano T, Simons IH, Beier A-MK, Ebersbach C, Aksoy C, Seed RI, et al. A systematic comparison of Antiandrogens identifies androgen receptor protein Stability as an Indicator for Treatment Response. Life. 2021;11(9):874.
pubmed: 34575023
pmcid: 8468615
doi: 10.3390/life11090874
Siciliano T, Sommer U, Beier AK, Stope MB, Borkowetz A, Thomas C, et al. The androgen hormone-Induced increase in Androgen receptor protein expression is caused by the autoinduction of the androgen receptor translational activity. Curr Issues Mol Biol. 2022;44(2):597–608.
pubmed: 35723327
pmcid: 8928990
doi: 10.3390/cimb44020041
Zaalberg A, Pottendorfer E, Zwart W, Bergman AM. It takes two to Tango: the interplay between prostate Cancer and its Microenvironment from an epigenetic perspective. Cancers [Internet]. 2024; 16(2).
Linder S, Hoogstraat M, Stelloo S, Eickhoff N, Schuurman K, de Barros H, et al. Drug-Induced Epigenomic Plasticity reprograms Circadian Rhythm Regulation to drive prostate Cancer toward androgen independence. Cancer Discov. 2022;12(9):2074–97.
pubmed: 35754340
pmcid: 7613567
doi: 10.1158/2159-8290.CD-21-0576
Niu Y, Altuwaijri S, Lai K-P, Wu C-T, Ricke WA, Messing EM et al. Androgen receptor is a tumor suppressor and proliferator in prostate cancer. Proceedings of the National Academy of Sciences. 2008;105(34):12182-7.
Calabrese EJ. Androgens: biphasic dose responses. Crit Rev Toxicol. 2001;31(4–5):517–22.
pubmed: 11504178
doi: 10.1080/20014091111794
Atri Roozbahani G, Kokal-Ribaudo M, Heidari Horestani M, Pungsrinont T, Baniahmad A. The protein composition of exosomes released by prostate cancer cells is distinctly regulated by androgen receptor-antagonists and -agonist to stimulate growth of target cells. Cell Communication Signal. 2024;22(1):219.
doi: 10.1186/s12964-024-01584-z
Mirzakhani K, Kallenbach J, Rasa SMM, Ribaudo F, Ungelenk M, Ehsani M, et al. The androgen receptor-lncRNASAT1-AKT-p15 axis mediates androgen-induced cellular senescence in prostate cancer cells. Oncogene. 2022;41(7):943–59.
pubmed: 34667276
doi: 10.1038/s41388-021-02060-5
Melnyk JE, Steri V, Nguyen HG, Hwang YC, Gordan JD, Hann B, et al. Targeting a splicing-mediated drug resistance mechanism in prostate cancer by inhibiting transcriptional regulation by PKCβ1. Oncogene. 2022;41(11):1536–49.
pubmed: 35087237
pmcid: 8913362
doi: 10.1038/s41388-022-02179-z
Van Goubergen J, Handle F, Cronauer MV, Santer FR. Abstract 2692: identification of functional single nucleotide polymorphisms in cryptic exon 3 of the androgen receptor gene. Cancer Res. 2022;82(12Supplement):2692.
doi: 10.1158/1538-7445.AM2022-2692
Goubergen J, Handle F, Cronauer MV, Santer F. Identification of functional single nucleotide polymorphisms in cryptic exon 3 of the androgen receptor gene. Eur Urol Open Sci. 2022;44:S183.
doi: 10.1016/S2666-1683(22)01947-4
Van Goubergen J, Perina M, Handle F, Morales E, Kremer A, Schmidt O et al. Die Spleißapparat-Komponente SRSF9 reguliert in einer rs5918762-abhängigen Weise die Expression von ARV7 [Abstractbook]. 2024 [cited 2024 02/06/2024]. https://www.egms.de/static/en/meetings/urobay2024/24urobay29.shtml
Chou J, Quigley DA, Robinson TM, Feng FY, Ashworth A. Transcription-Associated cyclin-dependent kinases as targets and biomarkers for Cancer Therapy. Cancer Discov. 2020;10(3):351–70.
pubmed: 32071145
doi: 10.1158/2159-8290.CD-19-0528
Rescigno P, Gurel B, Pereira R, Crespo M, Rekowski J, Rediti M, et al. Characterizing CDK12-Mutated prostate cancers. Clin Cancer Res. 2021;27(2):566–74.
pubmed: 32988971
doi: 10.1158/1078-0432.CCR-20-2371
Gondane A, Itkonen HM. Revealing the history and mystery of RNA-Seq. Curr Issues Mol Biol. 2023;45(3):1860–74.
pubmed: 36975490
pmcid: 10047236
doi: 10.3390/cimb45030120
Sun R, Wei T, Ding D, Zhang J, Chen S, He HH, et al. CYCLIN K down-regulation induces androgen receptor gene intronic polyadenylation, variant expression and PARP inhibitor vulnerability in castration-resistant prostate cancer. Proc Natl Acad Sci U S A. 2022;119(39):e2205509119.
pubmed: 36129942
pmcid: 9522376
doi: 10.1073/pnas.2205509119
Liang J, Gondane A, Itkonen HM. CDK12-inactivation-induced MYC signaling causes dependency on the splicing kinase SRPK1. Mol Oncol. 2024.
Pallasaho G, Duveau. Thomas, Loda, Itkonen. Compromised CDK12 activity causes dependency on the non-essential spliceosome components. bioRxiv2021.
Chen EX, Hotte S, Hirte H, Siu LL, Lyons J, Squires M, et al. A phase I study of cyclin-dependent kinase inhibitor, AT7519, in patients with advanced cancer: NCIC clinical trials Group IND 177. Br J Cancer. 2014;111(12):2262–7.
pubmed: 25393368
pmcid: 4264455
doi: 10.1038/bjc.2014.565
Mahadevan D, Plummer R, Squires MS, Rensvold D, Kurtin S, Pretzinger C, et al. A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors. Ann Oncol. 2011;22(9):2137–43.
pubmed: 21325451
doi: 10.1093/annonc/mdq734
Hu Q, Poulose N, Girmay S, Heleva A, Doultsinos D, Gondane A, et al. Inhibition of CDK9 activity compromises global splicing in prostate cancer cells. RNA Biol. 2021;18(sup2):722–9.
pubmed: 34592899
pmcid: 8782174
doi: 10.1080/15476286.2021.1983287
Gondane A, Poulose N, Walker S, Mills IG, Itkonen HM. O-GlcNAc transferase maintains metabolic homeostasis in response to CDK9 inhibition. Glycobiology. 2022;32(9):751–9.
pubmed: 35708495
pmcid: 9387508
Itkonen HM, Poulose N, Steele RE, Martin SES, Levine ZG, Duveau DY, et al. Inhibition of O-GlcNAc transferase renders prostate Cancer cells dependent on CDK9. Mol Cancer Res. 2020;18(10):1512–21.
pubmed: 32611550
pmcid: 7541471
doi: 10.1158/1541-7786.MCR-20-0339
Yalala S, Gondane A, Poulose N, Liang J, Mills IG, Itkonen HM. CDK9 inhibition activates innate immune response through viral mimicry. Faseb j. 2024;38(8):e23628.
pubmed: 38661032
doi: 10.1096/fj.202302375R
Barfeld SJ, Urbanucci A, Itkonen HM, Fazli L, Hicks JL, Thiede B, et al. c-Myc antagonises the transcriptional activity of the androgen receptor in prostate Cancer Affecting Key Gene Networks. EBioMedicine. 2017;18:83–93.
pubmed: 28412251
pmcid: 5405195
doi: 10.1016/j.ebiom.2017.04.006
Pernigoni N, Zagato E, Calcinotto A, Troiani M, Mestre RP, Calì B, et al. Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis. Science. 2021;374(6564):216–24.
pubmed: 34618582
doi: 10.1126/science.abf8403
Sharp A, Coleman I, Yuan W, Sprenger C, Dolling D, Rodrigues DN, et al. Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer. J Clin Invest. 2019;129(1):192–208.
pubmed: 30334814
doi: 10.1172/JCI122819
Calcinotto A, Spataro C, Zagato E, Di Mitri D, Gil V, Crespo M, et al. IL-23 secreted by myeloid cells drives castration-resistant prostate cancer. Nature. 2018;559(7714):363–9.
pubmed: 29950727
pmcid: 6461206
doi: 10.1038/s41586-018-0266-0
Guo C, Sharp A, Gurel B, Crespo M, Figueiredo I, Jain S, et al. Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance. Nature. 2023;623(7989):1053–61.
pubmed: 37844613
pmcid: 10686834
doi: 10.1038/s41586-023-06696-z
Liu C, Lou W, Yang JC, Liu L, Armstrong CM, Lombard AP, et al. Proteostasis by STUB1/HSP70 complex controls sensitivity to androgen receptor targeted therapy in advanced prostate cancer. Nat Commun. 2018;9(1):4700.
pubmed: 30446660
pmcid: 6240084
doi: 10.1038/s41467-018-07178-x
Ferraldeschi R, Welti J, Powers MV, Yuan W, Smyth T, Seed G, et al. Second-generation HSP90 inhibitor Onalespib blocks mRNA splicing of androgen receptor variant 7 in prostate Cancer cells. Cancer Res. 2016;76(9):2731–42.
pubmed: 27197266
pmcid: 4874658
doi: 10.1158/0008-5472.CAN-15-2186
Nappi L, Aguda AH, Nakouzi NA, Lelj-Garolla B, Beraldi E, Lallous N, et al. Ivermectin inhibits HSP27 and potentiates efficacy of oncogene targeting in tumor models. J Clin Invest. 2020;130(2):699–714.
pubmed: 31845908
doi: 10.1172/JCI130819
Shrestha L, Bolaender A, Patel HJ, Taldone T. Heat shock protein (HSP) Drug Discovery and Development: Targeting Heat Shock proteins in Disease. Curr Top Med Chem. 2016;16(25):2753–64.
pubmed: 27072696
pmcid: 4995156
doi: 10.2174/1568026616666160413141911
Sommer U, Siciliano T, Ebersbach C, Beier A-MK, Stope MB, Jöhrens K, et al. Impact of androgen receptor activity on prostate-specific membrane Antigen expression in prostate Cancer cells. Int J Mol Sci. 2022;23(3):1046.
pubmed: 35162969
pmcid: 8835452
doi: 10.3390/ijms23031046
Peters SMB, Prive BM, de Bakker M, de Lange F, Jentzen W, Eek A, et al. Intra-therapeutic dosimetry of [(177)Lu]Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcome. Eur J Nucl Med Mol Imaging. 2022;49(2):460–9.
pubmed: 34218300
doi: 10.1007/s00259-021-05471-4
Violet J, Jackson P, Ferdinandus J, Sandhu S, Akhurst T, Iravani A, et al. Dosimetry of < sup > 177 Lu-PSMA-617 in metastatic castration-resistant prostate Cancer: correlations between Pretherapeutic Imaging and whole-body tumor dosimetry with treatment outcomes. J Nucl Med. 2019;60(4):517–23.
pubmed: 30291192
doi: 10.2967/jnumed.118.219352
Mah LJ, El-Osta A, Karagiannis TC. γH2AX: a sensitive molecular marker of DNA damage and repair. Leukemia. 2010;24(4):679–86.
pubmed: 20130602
doi: 10.1038/leu.2010.6
Cornelissen B, Kersemans V, Darbar S, Thompson J, Shah K, Sleeth K, et al. Imaging DNA damage in vivo using gammaH2AX-targeted immunoconjugates. Cancer Res. 2011;71(13):4539–49.
pubmed: 21586614
pmcid: 3130133
doi: 10.1158/0008-5472.CAN-10-4587
Marinescu IM, Rogg M, Spohn S, von Büren M, Kamps M, Jilg CA, et al. Ex vivo γH2AX assay for tumor radiosensitivity in primary prostate cancer patients and correlation with clinical parameters. Radiat Oncol. 2022;17(1):163.
pubmed: 36199143
pmcid: 9533509
doi: 10.1186/s13014-022-02131-1
O’Neill E, Mosley M, Cornelissen B. Imaging DNA damage response by γH2AX in vivo predicts treatment response to Lutetium-177 radioligand therapy and suggests senescence as a therapeutically desirable outcome. Theranostics. 2023;13(4):1302–10.
pubmed: 36923536
pmcid: 10008745
doi: 10.7150/thno.82101
Reissig F, Bauer D, Zarschler K, Novy Z, Bendova K, Ludik M-C et al. Towards Targeted Alpha Therapy with Actinium-225: Chelators for Mild Condition Radiolabeling and Targeting PSMA—A Proof of Concept Study. Cancers [Internet]. 2021; 13(8).
Kratochwil C, Bruchertseifer F, Giesel FL, Weis M, Verburg FA, Mottaghy F, et al. 225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-resistant prostate Cancer. J Nucl Med. 2016;57(12):1941–4.
pubmed: 27390158
doi: 10.2967/jnumed.116.178673
Usmani S, Rasheed R, Al Kandari F, Marafi F, Naqvi SAR. 225Ac prostate-specific membrane Antigen Posttherapy α imaging: comparing 2 and 3 photopeaks. Clin Nucl Med. 2019;44(5):401–3.
pubmed: 30932973
doi: 10.1097/RLU.0000000000002525
Michler E, Kästner D, Brogsitter C, Pretze M, Hartmann H, Freudenberg R, et al. First-in-human SPECT/CT imaging of [212Pb]Pb-VMT-α-NET in a patient with metastatic neuroendocrine tumor. Eur J Nucl Med Mol Imaging. 2024;51(5):1490–2.
pubmed: 37991526
doi: 10.1007/s00259-023-06529-1
Emmett L, Buteau J, Papa N, Moon D, Thompson J, Roberts MJ, et al. The Additive Diagnostic Value of prostate-specific membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the diagnosis of prostate Cancer (PRIMARY): a prospective Multicentre Study. Eur Urol. 2021;80(6):682–9.
pubmed: 34465492
doi: 10.1016/j.eururo.2021.08.002
Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395(10231):1208–16.
pubmed: 32209449
doi: 10.1016/S0140-6736(20)30314-7
Horsley PJ, Koo CM, Eade T, Hsiao E, Emmett L, Brown C, et al. Mapping of local recurrences after Radical Prostatectomy using 68-Gallium-prostate-specific membrane Antigen Positron Emission Tomography/Computed tomography: implications for Postprostatectomy Radiation Therapy Clinical Target volumes. Int J Radiat Oncol Biol Phys. 2023;115(1):106–17.
pubmed: 35716849
doi: 10.1016/j.ijrobp.2022.05.044
Emmett L, Subramaniam S, Crumbaker M, Nguyen A, Joshua AM, Weickhardt A, et al. [(177)Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 2024;25(5):563–71.
pubmed: 38621400
doi: 10.1016/S1470-2045(24)00135-9
Suman S, Parghane RV, Joshi A, Prabhash K, Talole S, Basu S, Combined. (177) Lu-PSMA-617 PRLT and abiraterone acetate versus (177) Lu-PSMA-617 PRLT monotherapy in metastatic castration-resistant prostate cancer: An observational study comparing the response and durability. The Prostate. 2021;81(15):1225-34.
Schuurman T, Witteveen P, Wall E, Passier J, Huitema A, Amant F et al. Tamoxifen and pregnancy: an absolute contraindication? Breast Cancer Res Treat. 2019;175.
Puhr M, Eigentler A, Handle F, Hackl H, Ploner C, Heidegger I, et al. Targeting the glucocorticoid receptor signature gene Mono Amine Oxidase-A enhances the efficacy of chemo- and anti-androgen therapy in advanced prostate cancer. Oncogene. 2021;40(17):3087–100.
pubmed: 33795839
pmcid: 8084733
doi: 10.1038/s41388-021-01754-0